Toxicological Studies and Biocompatibility in Russian Medical Device Registration

1. Key takeaways

Toxicological studies are one of the three forms of conformity assessment in Russian national registration, and their core purpose is the evaluation of biological safety. Whether a study is required depends on the nature, site and duration of the contact between the device and the human body. The evaluation methods are grounded in the Russian transposition of the ISO 10993 series, published as the GOST ISO 10993 standards, while for products taking the Union path there is a separate decision of the Eurasian Economic Commission on biological evaluation. Sponsors should therefore determine the evaluation matrix from the contact profile at the very start of the project, because the contact profile also drives the choice of testing methods and the depth of the study programme.

The toxicological study report follows the recommended format of Annex 2 of Order No. 421n, and it must present the biological safety conclusion in a form that the expert organisation can reconcile with the other result documents in the dossier. Material choices made during product development largely predetermine how heavy this part of the dossier will be: well-characterised materials with established biological evaluation histories keep the programme lean, while novel materials can push the project towards human clinical trials under the grounds listed in the conformity assessment procedures.

2. Legal basis

The instruments governing toxicological studies and biological evaluation are summarised below.

Note: the publication date of EEC Decision No. 38 was not obtained from the official text at the time of writing; this article refers to the decision only for the methodological comparison between the two paths and does not cite specific provisions.

3. Expert insights

Insight 1: the three contact elements determine the depth of evaluation. The nature of contact (surface-contacting devices, externally communicating devices, implantable devices), the contact site (intact skin, mucous membranes, blood, the central nervous system and other tissues) and the contact duration (short term, up to 60 minutes; prolonged, from 60 minutes to 30 days; long term, more than 30 days) together constitute the evaluation matrix. Whenever any of the three elements moves to a more invasive or longer category, the set of evaluation endpoints grows accordingly. Determining this matrix in writing at project start prevents disputes with laboratories and expert organisations later, and it makes the testing budget predictable.

Insight 2: novel materials are the variable most likely to trigger additional evaluation. Item “e” of p. 31 of Order No. 421n lists materials whose biological effects have not been studied, as well as known materials applied to new organ or tissue types or used over longer contact durations, among the situations requiring human clinical trials. Material selection at the design stage therefore fixes the downstream cost of registration. A material that is familiar in one application class may become a clinical-trial trigger in another class or at a longer duration, and sponsors should evaluate this before committing to a design.

Insight 3: sterile and non-sterile variants of the same registration unit diverge under the same framework. Where a registration unit contains both sterile and non-sterile models, the toxicological evaluation and sterilisation validation are handled differently for each status. The recommended practice is to separate the cases or to define precisely the sterile status of the registration object, so that the expert organisation does not encounter contradictory statements between the test reports, the labels and the instructions for use.

4. Practical recommendations

1. At project initiation, compile a material list including additives, colorants and adhesives, and confirm the biological evaluation history of each material against the contact profile.
2. Agree with the testing laboratory on the methodological correspondence between the GB/T 16886 series and the GOST ISO 10993 series, so that existing reports are not rejected on formal grounds.
3. Avoid mixed sterile and non-sterile filings within one registration unit, and state the sterile status of the registration object consistently across all documents.
4. Where novel materials cannot be avoided, budget early for the possibility of human clinical trials under item “e” of p. 31 rather than discovering the requirement during review.
5. Record the contact nature, site and duration in the dossier narrative so that the evaluation matrix can be verified without reverse-engineering the intended use.

5. Verification checklist

• □ The three contact elements have been determined and the evaluation endpoint matrix derived from them
• □ The toxicological study report follows the recommended format of Annex 2 of Order No. 421n
• □ Novel materials and prolonged contact situations have been assessed under item “e” of p. 31
• □ The material list has been submitted to the laboratory for methodological confirmation
• □ The sterile or non-sterile status of the registration object is stated clearly and consistently

Regulatory information verified as of October 29, 2026.

GRZAN provides biological safety and toxicology support for companies entering the Russian market, including evaluation matrix design under the contact nature, site and duration framework, preparation of toxicological study documentation in the format of Annex 2 of Order No. 421n, and coordination with accredited laboratories on methodological alignment. For assistance with toxicological studies and conformity documents in Russia, contact us at info@grzanglobal.com.